Literature DB >> 7635097

Northern epilepsy syndrome: clinical course and the effect of medication on seizures.

A Hirvasniemi1, P Herrala, J Leisti.   

Abstract

We describe the clinical course and treatment of 19 patients with the Northern epilepsy syndrome, an autosomal recessively inherited epilepsy with associated mental deterioration. The clinical course could be divided into three successive stages. The first stage continued from the onset of epilepsy until puberty. Seizures began at a mean age of 6.6 years and consisted predominantly of generalized tonic-clonic convulsions (GTC) and, transiently, also of complex partial seizures (CPS). Until puberty, seizure frequency increased in most patients from one attack in 1-2 months to one to two attacks weekly. Seizures did not respond to phenytoin (PHT) or carbamazepine (CBZ), were transiently controlled by valproate (VPA) and phenobarbital (PB), but were effectively treated only by clonazepam (CZP). Mental deterioration began 2-5 years after the onset of epilepsy and was most rapid before adulthood, a time when the seizures were also most frequent. The second stage is marked by fewer seizures, further mental deterioration, and less rapid progression. All patients were demented (I.Q. < 70) by age of 30 years. The first signs of motor clumsiness also appeared then. The third stage was one of permanent disability and usually began in middle age. Seizures were few, but the patients were clumsy and had marked equilibrium difficulties.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7635097     DOI: 10.1111/j.1528-1157.1995.tb01616.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  4 in total

1.  Genetic and physical mapping of the progressive epilepsy with mental retardation (EPMR) locus on chromosome 8p.

Authors:  S Ranta; A E Lehesjoki; A Hirvasniemi; J Weissenbach; B Ross; S M Leal; A de la Chapelle; T C Gilliam
Journal:  Genome Res       Date:  1996-05       Impact factor: 9.043

2.  Brief report: clonazepam behavioral side effects with an individual with mental retardation.

Authors:  John E Kalachnik; Thomas E Hanzel; Robert Sevenich; Stuart R Harder
Journal:  J Autism Dev Disord       Date:  2003-06

Review 3.  The CLN3 gene and protein: What we know.

Authors:  Myriam Mirza; Anna Vainshtein; Alberto DiRonza; Uma Chandrachud; Luke J Haslett; Michela Palmieri; Stephan Storch; Janos Groh; Niv Dobzinski; Gennaro Napolitano; Carolin Schmidtke; Danielle M Kerkovich
Journal:  Mol Genet Genomic Med       Date:  2019-09-30       Impact factor: 2.183

4.  AAV9 Gene Therapy Increases Lifespan and Treats Pathological and Behavioral Abnormalities in a Mouse Model of CLN8-Batten Disease.

Authors:  Tyler B Johnson; Katherine A White; Jon J Brudvig; Jacob T Cain; Logan Langin; Melissa A Pratt; Clarissa D Booth; Derek J Timm; Samantha S Davis; Brandon Meyerink; Shibi Likhite; Kathrin Meyer; Jill M Weimer
Journal:  Mol Ther       Date:  2020-09-24       Impact factor: 11.454

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.